Characteristic features of cases reported with hyperacute ICH following CAS

Author	Age (y)/Sex	Vessel Treated (NASCET)	Other Territories	Vascular Risk Factors	Time from Last Symptom	Radiographic Pathologies before Treatment			Blood Pressure (mmHg)			Anticoagulation (Procedural)		Time between End of Procedure and Setup of Neurologic Event	Localization of ICH	HPS Suspect Prodro-mata	Clinical Out-come
Author	Age (y)/Sex	Vessel Treated (NASCET)	Other Territories	Vascular Risk Factors	Time from Last Symptom	Embolic	Hemodynamic	Microangio-pathic	During Procedure	After Procedure	During Neurologic Event	Heparin	Others	Time between End of Procedure and Setup of Neurologic Event	Localization of ICH	HPS Suspect Prodro-mata	Clinical Out-come
McCabe et al⁹	68/M	Left ICA (95%)	No data	Smoking, alcohol	5 mo, incomplete remission	Cortical	None	Moderate periventricular	160/90–175/105	140–160/95	150/85	5000 IU	ASA, dipyridamole	7 h	Ipsilateral basal ganglia	None	Fatal
Moriet al¹⁰	71/M	Left ICA (99%)	No data	Hypertension	None, recurrent TIAs	None	None	Yes	≤142 systolic	No data	170–190 systolic	10 000 IU	Warfarin, ticlopidin	4 h	Ipsilateral basal ganglia	None	Fatal
Morrishet al⁶	87/M	Left ICA (95%)	No significant stenosis in contralateral ICA	No data	4 mo	None	None	Subcortical	No data	110/60	125/80	7000 IU	ASA, ticlopidin	10 h	No data	None	Fatal
Morrishet al⁶	62/F	Right ICA (95%)	No significant stenosis in contralateral ICA	No data	6 wk	Large cortical	None	None	No data	173/64	173/64	9000 IU	ASA, ticlopidin	15 min	Ipsilateral basal ganglia	None	Fatal
Chamorroet al¹¹	43/M	Right ICA (95%)	No stenosis	Hypertension	7 d	Acute embolic	None	Lacunar	135/75–180/80	100/60–125/60	180/75	5000 IU	ASA, clopidogrel, urokinase	∼6 h	Contralateral basal ganglia	None	Fatal
Qureshiet al¹²	66/F	ICA (99%)	No data	Hypertension, smoking, hyperlipidemia	2 d after ischemic stroke	None	None	Lacunar	No data	Max. 165 systolic	No data	ACT: 356 s	ASA, clopidogrel, abciximab	1 h	Basal ganglia	None	Fatal
Qureshiet al¹²	56/M	ICA (90%)	No data	Hypertension, coronary and peripheral artery disease	4 d after TIA	None	None	None	No data	Max. 199 systolic	No data	ACT: 180 s	ASA, clopidogrel, abciximab	8 h	Basal ganglia	None	Fatal
Qureshiet al¹²	61/M	ICA (90%)	No data	Coronary and peripheral artery disease	4 wk after ischemic stroke	Multiple small infarcts ipsilateral to stenosis	None	None	No data	Max. 187 systolic	No data	ACT: 320 s	ASA, clopidogrel, abciximab	10 min	Lobar	None	Fatal
Qureshiet al¹²	46/F	ICA (80%)	No data	Hypertension, smoking	1 d after TIA	None	None	None	No data	Max. 260 systolic	No data	ACT: 273 s	ASA, clopidogrel, abciximab	1 h	Lobar	None	Fatal
Friedmanet al¹³	82/M	Right ICA (90%)	Left ICA (60%), no collateralization from anterior or posterior communicating arteries	Positive family history	Few days	None	Yes, restricted diffusion	None	∼140 systolic	∼140 systolic	No data	5000 IU	ASA, clopidogrel	45 min	Ipsilateral basal ganglia	None	Fatal
Abou-Cheblet al¹⁴	Not applicable	Left ICA (99%)	Right ICA (80%)	Hypertension	Not applicable							∼5000 IU (ACT > 250 s)	ASA, clopidogrel	1 h	Ipsilateral basal ganglia	None	Fatal
Case reported	65/F	Right ICA (95%)	Left ICA (80%), proximal VA stenosis bilateral	Hypertension, smoking, alcohol, positive family history	Maximum 14 d, incomplete remission	Cortical	Yes, restricted diffusion	Mild	140/70	120/70	Max. 160 systolic	5000 IU (ACT: 278 s)	ASA, clopidogrel	30 min	Ipsilateral basal ganglia	None	Fatal

Note:—NASCET indicates North American Symptomatic Carotid Endarterectomy Trial; ICA, internal carotid artery; VA, vertebral artery; TIA, transient ischemic attack; ASA, acetyl salicylic acid; ACT, activated clotting time.